Literature DB >> 12018924

Oral cavity as a potential source of gastric reinfection by Helicobacter pylori.

Elzbieta Karczewska1, Joanna E Konturek, Peter C Konturek, Marta Cześnikiewicz, Edward Sito, Władysław Bielański, Nina Kwiecień, Wojciech Obtułowicz, Witold Ziemniak, Jolanta Majka, Eckhart G Hahn, Stanislaw J Konturek.   

Abstract

Helicobacter pylori (Hp) is a common pathogen colonizing the a gastric mucosa, but some reports indicated that it may also be found in the oral cavity, which could serve as a reservoir of the bacteria and a source of gastric reinfection. Accordingly, we aimed to study whether the oral cavity, particularly gingival pockets, are colonized by Hp and whether it could be the source of gastric reinfection. We studied 329 patients with dyspeptic symptoms (257 with chronic gastritis, 15 with gastric ulcer, and 57 with duodenal ulcer). The [13C]urea breath test (UBT), gastroscopy, and Hp culture from gastric biopsies were carried out, and material was collected from the oral cavity (gingival pocket) for bacteriological culture and genomic DNA studies. The serum was obtained for anti-Hp IgG and anti-CagA assays and saliva for anti-Hp IgA determination using the ELISA technique. Bacteria in material from gingival pockets and biopsies from the corpus and antrum of stomach of 30 DU patients before and after Hp eradication were also examined by PCR technique, using primers specific for 16S rRNA. All Hp-positive patients (276) were subjected to one week of triple therapy (omeprazole 2 x 20 mg twice a day, clarithromycin 2 x 500 mg twice a day, and metronidazole 2 x 500 mg twice a day). The measurements described above were then repeated at four weeks and six months. Bacteriological culture showed the presence of Hp in the material from oral cavity in about 50% of patients, whereas UBT, used as a gold standard, revealed gastric Hp infection in about 84% of these patients. The eradication was successful in the majority of patients (87%), but about 13% of them were still Hp positive after four weeks and about 21% after six months. Four weeks after Hp therapy, Hp was found in culture from oral samples in 23% (P < 0.05 vs initial) and after six months in 35.1%. The IgA levels recorded in saliva were in a close agreement with UBT results. Hp DNA assessed by PCR in 30 DUs before eradication of Hp was detected in 95% of antral mucosa, 90% in corpus mucosa, and in 35% of gingival pocket material, and after eradication therapy Hp DNA values fell to 25%, 20%, and 10%, respectively. In conclusion, Hp is commonly detected in the oral cavity of patients with dyspeptic symptoms, but the gastric reinfection does not appear to occur in the patients despite oral Hp colonization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018924     DOI: 10.1023/a:1015017502772

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Oral cavity as permanent reservoir of Helicobacter pylori and potential source of reinfection.

Authors:  J Pytko-Polonczyk; S J Konturek; E Karczewska; W Bielański; A Kaczmarczyk-Stachowska
Journal:  J Physiol Pharmacol       Date:  1996-03       Impact factor: 3.011

2.  Helicobacter pylori in the oral cavity reflects handling of contaminants but not gastric infection.

Authors:  C Doré-Davin; M Heitz; H Yang; M Herranz; A L Blum; I Corthésy-Theulaz
Journal:  Digestion       Date:  1999       Impact factor: 3.216

3.  Evaluation of Pyloriset Screen, a rapid whole-blood diagnostic test for Helicobacter pylori infection.

Authors:  A Oksanen; L Veijola; P Sipponen; K O Schauman; H Rautelin
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

4.  Helicobacter pylori-gastrin link in MALT lymphoma.

Authors:  P C Konturek; S J Konturek; T Starzyska; K Marlicz; W Bielanski; P Pierzchalski; E Karczewska; A Hartwich; K Rembiasz; M Lawniczak; W Ziemniak; E C Hahn
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

5.  Association of Helicobacter pylori infection with coronary heart disease.

Authors:  P Pieniazek; E Karczewska; A Duda; W Tracz; M Pasowicz; S J Konturek
Journal:  J Physiol Pharmacol       Date:  1999-12       Impact factor: 3.011

6.  Activation of genes for superoxide dismutase, interleukin-1beta, tumor necrosis factor-alpha, and intercellular adhesion molecule-1 during healing of ischemia-reperfusion-induced gastric injury.

Authors:  P C Konturek; A Duda; T Brzozowski; S J Konturek; S Kwiecien; D Drozdowicz; R Pajdo; H Meixner; E G Hahn
Journal:  Scand J Gastroenterol       Date:  2000-05       Impact factor: 2.423

7.  Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.

Authors:  T U Kosunen; K Seppälä; S Sarna; P Sipponen
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

8.  Cytomegalovirus (CMV) and Helicobacter pylori (HP) found in oral mucosal ulcers.

Authors:  R Leimola-Virtanen; R P Happonen; S Syrjänen
Journal:  J Oral Pathol Med       Date:  1995-01       Impact factor: 4.253

Review 9.  Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.

Authors:  M J Blaser
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

10.  Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk.

Authors:  M J Blaser; P H Chyou; A Nomura
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

View more
  8 in total

Review 1.  H pylori recurrence after successful eradication.

Authors:  Yaron Niv
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

2.  Detection of Helicobacter pylori in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential.

Authors:  Petr Lukeš; Emil Pavlík; Bela Potuznikova; Eva Nartova; Eva Foltynova; Jan Plzak; Rami Katra; Ivan Sterzl; Jirina Bartunkova; Jan Betka; Jaromir Astl
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-07       Impact factor: 2.503

Review 3.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

4.  Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Takayuki Imada; Tetsuji Okuno; Tomowo Yoshida; Kenji Yokota; Keiji Oguma; Masahide Kita; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2012-02-17       Impact factor: 7.527

Review 5.  An association between Helicobacter pylori and upper respiratory tract disease: fact or fiction?

Authors:  Shin Kariya; Mitsuhiro Okano; Kazunori Nishizaki
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Saliva secretion and efficacy of helicobacter pylori eradication in peptic ulcer patients.

Authors:  M Vahedi; Ar Khalilian; Sh Abdollahzadeh; N Shafiei
Journal:  J Dent (Tehran)       Date:  2011-12-20

7.  Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.

Authors:  Min Soo Kim; Nayoung Kim; Sung Eun Kim; Hyun Jin Jo; Cheol Min Shin; Young Soo Park; Dong Ho Lee
Journal:  BMC Gastroenterol       Date:  2013-09-19       Impact factor: 3.067

8.  Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study.

Authors:  Yong Xie; Conghua Song; Hong Cheng; Canxia Xu; Zhenyu Zhang; Jiangbin Wang; Lijuan Huo; Qin Du; Jianming Xu; Ye Chen; Xiaomei Zhang; Guoxin Zhang; Guibin Yang; Xiuli Zuo; Tao Guo; Yapi Lu; Fen Wang; Xuehong Wang; Kun Zhuang; Shiyao Chen; Wenzhong Liu; Nonghua Lu
Journal:  Emerg Microbes Infect       Date:  2020-03-11       Impact factor: 7.163

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.